Ocugen, Inc. (OCGN)
| Market Cap | 2.06B |
| Revenue (ttm) | 42,620 |
| Net Income (ttm) | -37.50M |
| Shares Out | 186.30M |
| EPS (ttm) | -0.28 |
| PE Ratio | n/a |
| Forward PE | 4.61 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 12 |
| Last Price | $8.61 |
| Previous Close | $9.90 |
| Change ($) | -1.29 |
| Change (%) | -13.03% |
| Day's Open | 9.79 |
| Day's Range | 8.52 - 10.63 |
| Day's Volume | 67,974,911 |
| 52-Week Range | 0.17 - 18.77 |
Small-cap stocks in the biotech space have been in a slump, but these seven companies could see big moves just around the corner. The post 7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts appe...
These penny stocks hit it out of the park in 2021 & continue to climb in May. The post Former Penny Stocks To Watch Making Their Mark In 2021 appeared first on Penny Stocks to Buy, Picks, News and Infor...
Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.
With clinical data to support Ocugen's product candidate to treat multiple eye conditions, OCGN stock isn't just your typical "vaccine stock." The post Take a Look at Ocugen's Work on Eye Diseases, Not ...
This coronavirus vaccine drugmaker has made investors rich in a very short period. Can it sustain its run?
Ocugen released a bunch of seemingly positive news in recent days. Yet OCGN stock tanked anyway.
One security grew $35,000 into more than $9 million since early November.
So what did the stock market do today? Investors are digesting what big moves in Dogecoin and SafeMoon mean for the market.
Ocugen (OCGN) stock taking a beating on Friday following the release of the biopharmaceutical company's earnings report for Q1 2021. The post OCGN Stock: Why Red-Hot Ocugen Is Plunging Again Today appea...
Investors didn't get what they wanted in the biotech's Q1 update.
Ocugen (OCGN) miss earnings and revenues estimates in the first quarter of 2021. Stock down.
OGCN Stock had a nice run in recent weeks but faces risks of a sharp pullback that could lead to paper losses for speculators. The post Ocugen Stock Has a Big Pullback Coming, and That Will Be Your Chan...
OCGN stock soared on a deal to commercialize Bharat Biotech's Covaxin in the U.S., but the rollout comes with a lot of challenges. The post Ocugen Stock Is a Risky Proposition Despite Its High Valuation...
Conference Call and Webcast Today at 8:30 a.m. ET
The biotech faces some big challenges.
Here's how the biotechs compare on several key fronts.
Ocugen Inc (NASDAQ: OCGN) has announced the presentation of new preclinical data evaluating the efficacy of OCU200 in in-vitro and in-vivo models for ocular neovascular diseases. The data will be presen...
Let us take a look at three small biotech companies, RDUS, CRON and OCGN, which are gearing up for their earnings release.
Ocugen insiders have been selling shares ahead of Friday's earnings report. OCGN stock had touched a six-month high to start off the week.
No U.S. government official has made positive comments about approving Covaxin and the Covaxin trials do not seem to meet the FDA's preferences. OCGN stock is a short.
OCGN stock has soared on positive vaccine data. But investors must remember that Ocugen's market and experience are sharply limited.
Ocugen had a strong April gaining a whopping 87% for the month. OCGN stock is now up 313% on the year.
Ocugen may be able to handle one of the biggest challenges facing vaccine makers.
Traders appear to be rotating out of these former highfliers.
These businesses could be in trouble once the pandemic is over.
The biotech could potentially help to protect people from new coronavirus variants.
MALVERN, Pa., May 03, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases ...
Covid-19 vaccine candidate Covaxin may inhibit transmissions, and OCGN stock traders should appreciate the promising recent clinical results. The post Stick With Ocugen As Its Covid-19 Vaccine Is the Re...
Ocugen Inc. (NASDAQ: OCGN) and Vaxart Inc. (NASDAQ: VXRT) are moving Monday. Ocugen shares gapped higher after the company's studies showed that COVAXIN is potentially effective against three key varian...
Penny stocks are hot right now and these former low-priced names are reaching for new highs this month. The post Former Penny Stocks To Watch Making New Highs In May 2021 appeared first on Penny Stocks ...
Ocugen (OCGN) is likely to provide update related to regulatory progress of its COVID-19 vaccine, Covaxin, in the United States when it reports first-quarter 2021 results.
Ocugen (OCGN) stock is soaring on Monday after announcing positive data concerning its Covaxin vaccine candidate for the novel coronavirus. The post OCGN Stock: The Big Study News Shooting Ocugen Shares...
Ocugen (NASDAQ: OCGN) shares are trading higher after the company announced studies showing COVAXIN is potentially effective against three key variants of SARS-CoV-2. In the ICMR studies, COVAXIN-vaccin...
Ocugen Inc (NASDAQ: OCGN) has announced that in a new study, COVAXIN demonstrated potential effectiveness against the Brazil variant of SARS-CoV-2, B.1.128.2. The study was conducted at the Indian Coun...
OCGN stock earlier seemed like a great play on a Covid-19 resurgence. But this narrative is not turning out so well.
MALVERN, Pa., May 03, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases ...
Yet, there's little to indicate it will obtain FDA approval. In addition, there's plenty suggesting that the U.S., already oversupplied when it comes to vaccines, has little need for Covaxin.
Recent volatility in a handful of so-called meme stocks is putting the spotlight back on the tussle between individual investors and short sellers, months after a wild ride in GameStop captivated Wall S...
OCGN stock got a bump on Phase 3 results but was met with market skepticism following its subsequent strategic moves. The post The Reasons to Avoid OCGN Stock Keep Piling Up appeared first on InvestorPl...
MALVERN, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness disease...
It comes down to timing.
Ocugen's (NASDAQ:OCGN) stock has been falling Tuesday, down 9.75% to a price of $10.55. Tuesday the stock has been traded at a volume of 24.93 million, about 43.69% of its recent 30-day volume average o...
This biotech obtained rights to sell a highly effective coronavirus vaccine in the U.S. Can it pull it off?
The bulls are on parade.
In this crazy Reddit-driven stock market, it's still important to understand why OCGN stock is hot. And why it's dangerous.
Ocugen, Inc. (NASDAQ: OCGN) shares are trading higher after the White House announced it would immediately make available specific raw materials needed by India to make COVID-19 vaccines. Ocugen is a bi...
OCGN has had several rallies off the head of good news. But is the occasional headline worth the stock's valuation?
As the vaccine rollout accelerates, investors remain on the fence as to how the Covaxin vaccine will impact OCGN stock in the near term. The post Why Investors Might Want to Start Getting Bullish on Ocu...
About OCGN
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development st... [Read more...]
| Industry Biotechnology | |
| CEO Shankar Musunuri | Employees 15 |
| Stock Exchange NASDAQ | Ticker Symbol OCGN |
Analyst Forecasts
According to 4 analysts, the average rating for Ocugen stock is "Buy." The 12-month stock price forecast is 7.75, which is a decrease of -9.99% from the latest price.